Cumberland Pharmaceutical... (CPIX)

NasdaqGS: CPIX · Real-Time Price · USD

7.91

-0.05 (-0.63%)

At close: Aug 12, 2026, 3:59 PM

7.92

+0.13%

After-hours: 7:34 PM

-0.63% (1D)

Bid	5.69
Market Cap	118.52M
Revenue (ttm)	44.3M
Net Income (ttm)	-3.2M
Beta	0.11
EPS (ttm)	-0.22
PE Ratio (ttm)	n/a
Forward PE	56.5
P/B (ttm)	6.80
P/S (ttm)	2.68
Earnings Date	Aug 10, 2021

Ask	10.17
Volume	72,038
Avg. Volume (20D)	109,488
Open	7.94
Previous Close	7.96
Day's Range	7.68 - 8.09
52-Week Range	1.85 - 8.45
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	Aug 3, 2026

About CPIX

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea ...

Sector Healthcare

IPO Date Aug 11, 2009

Employees 93

Stock Exchange NasdaqGS

Ticker Symbol CPIX

Website https://www.cumberlandpharma.com

Full Company Profile

Financial Performance

In 2025, Cumberland Pharmaceuticals's revenue was 44.52M, an increase of 17.57% compared to the previous year's 37.87M. Earnings were -2.84M, a decrease of -56.23%.

Financial Statements

Earnings Surprise

Cumberland Pharmaceuticals has released their quarterly earnings on May 11, 2021:

Revenue of $8.8M misses estimates by $0, with -18.79% YoY decline.

EPS of 0.07 exceeds estimates by 0.14, with 600.00% YoY growth.

Next Earnings Release

Cumberland Pharmaceuticals Inc. is scheduled to release its earnings on Aug 10, 2021, after market closes.
Analysts project revenue of ... Upgrade

News

1 week ago · GuruFocus.com

Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...

Company closes $100M Apotex deal, declares special dividend, and advances key clinical programs including DMD, systemic sclerosis, and IPF.

1 week ago · MarketBeat

Cumberland Pharmaceuticals Q2 Earnings Call Highlights

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovati...